14 research outputs found

    Comprehensive Screening for COVID-19 at St. Petersburg Oncology Centre

    Get PDF
    Background. Clinical reports on the coronavirus disease 2019 (COVID-19) suggest its higher incidence and worse outcomes in cancer patients. Considering a rapid pace of the severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) pandemic, more data on the risk of contagion and syndrome course is required with this patient group.Aim. Estimation of the infection rate in cancer patients managed at the Oncology Centre.Materials and methods. This retrospective study included cancer patients managed at the Oncology Centre between 9 April 2020 and 27 May 2020 and routinely tested for SARS-CoV-2 in polymerase chain reaction (PCR) assays and/or COVID-19 in chest computed tomography (CT).Results and discussion. A total of 2,628 patients were included in the study, with 119 (4.5 %) confirmed to have COVID-19; 45/119 were PCR-positive, 95/119 had viral pneumonia in CT, 21/119 were positive for both tests. A total of 47.9 % cases were asymptomatic, 11.8 % revealed a mild single-symptom disease. COVID-19 ended in death in 2 (2.5 %) of 80 cases with a known outcome. In PCR results of both patient and staff screening, the virus detection rate was 3.0 % and 2.4 %, respectively (p = 0.33).Conclusion. A COVID-19 screening revealed no significant difference in the risk of contagion between cancer patients and staff of the Oncology Centre. PCR tests may perform false negative for COVID-19 in cancer patients and should be coupled with CT scanning. The infection is asymptomatic or clinically mild in most other cases

    КомплСксноС обслСдованиС Π½Π° COVID-19 Π² ΠžΠ½ΠΊΠΎΠ»ΠΎΠ³ΠΈΡ‡Π΅ΡΠΊΠΎΠΌ Ρ†Π΅Π½Ρ‚Ρ€Π΅ Π‘Π°Π½ΠΊΡ‚-ΠŸΠ΅Ρ‚Π΅Ρ€Π±ΡƒΡ€Π³Π°

    Get PDF
    Background. Clinical reports on the coronavirus disease 2019 (COVID-19) suggest its higher incidence and worse outcomes in cancer patients. Considering a rapid pace of the severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) pandemic, more data on the risk of contagion and syndrome course is required with this patient group.Aim. Estimation of the infection rate in cancer patients managed at the Oncology Centre.Materials and methods. This retrospective study included cancer patients managed at the Oncology Centre between 9 April 2020 and 27 May 2020 and routinely tested for SARS-CoV-2 in polymerase chain reaction (PCR) assays and/or COVID-19 in chest computed tomography (CT).Results and discussion. A total of 2,628 patients were included in the study, with 119 (4.5 %) confirmed to have COVID-19; 45/119 were PCR-positive, 95/119 had viral pneumonia in CT, 21/119 were positive for both tests. A total of 47.9 % cases were asymptomatic, 11.8 % revealed a mild single-symptom disease. COVID-19 ended in death in 2 (2.5 %) of 80 cases with a known outcome. In PCR results of both patient and staff screening, the virus detection rate was 3.0 % and 2.4 %, respectively (p = 0.33).Conclusion. A COVID-19 screening revealed no significant difference in the risk of contagion between cancer patients and staff of the Oncology Centre. PCR tests may perform false negative for COVID-19 in cancer patients and should be coupled with CT scanning. The infection is asymptomatic or clinically mild in most other cases.Π’Π²Π΅Π΄Π΅Π½ΠΈΠ΅. ΠžΡ‚Ρ‡Π΅Ρ‚Ρ‹ ΠΎ коронавирусной Π±ΠΎΠ»Π΅Π·Π½ΠΈ 2019 (COVID-19) Ρƒ онкологичСских Π±ΠΎΠ»ΡŒΠ½Ρ‹Ρ… ΠΏΡ€Π΅Π΄ΠΏΠΎΠ»Π°Π³Π°ΡŽΡ‚ Π±ΠΎΠ»Π΅Π΅ Π²Ρ‹ΡΠΎΠΊΡƒΡŽ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π΅ΠΌΠΎΡΡ‚ΡŒ ΠΈΠ½Ρ„Π΅ΠΊΡ†ΠΈΠ΅ΠΉ ΠΈ Ρ…ΡƒΠ΄ΡˆΠΈΠ΅ исходы Π² этой Π³Ρ€ΡƒΠΏΠΏΠ΅. Учитывая быстроС распространСниС тяТСлого острого рСспираторного синдрома коронавируса 2 (SARS-CoV-2), Π½Π΅ΠΎΠ±Ρ…ΠΎΠ΄ΠΈΠΌΠ° Π΄ΠΎΠΏΠΎΠ»Π½ΠΈΡ‚Π΅Π»ΡŒΠ½Π°Ρ информация ΠΎ рисках зараТСния ΠΈ Ρ‚Π΅Ρ‡Π΅Π½ΠΈΠΈ COVID-19 Ρƒ этих ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ².ЦСль исслСдования. ЦСлью этого исслСдования Π±Ρ‹Π»ΠΎ ΠΎΠΏΡ€Π΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ частоты ΠΈΠ½Ρ„Π΅ΠΊΡ†ΠΈΠΈ Ρƒ онкологичСских Π±ΠΎΠ»ΡŒΠ½Ρ‹Ρ…, проходящих Π»Π΅Ρ‡Π΅Π½ΠΈΠ΅ Π² онкологичСском Ρ†Π΅Π½Ρ‚Ρ€Π΅.ΠœΠ°Ρ‚Π΅Ρ€ΠΈΠ°Π»Ρ‹ ΠΈ ΠΌΠ΅Ρ‚ΠΎΠ΄Ρ‹. ΠœΡ‹ рСтроспСктивно ΠΏΡ€ΠΎΠ°Π½Π°Π»ΠΈΠ·ΠΈΡ€ΠΎΠ²Π°Π»ΠΈ ΠΊΠΎΠ³ΠΎΡ€Ρ‚Ρƒ Π±ΠΎΠ»ΡŒΠ½Ρ‹Ρ… Ρ€Π°ΠΊΠΎΠΌ, ΠΊΠΎΡ‚ΠΎΡ€Ρ‹Π΅ наблюдались ΠΈ ΠΏΡ€ΠΎΡ…ΠΎΠ΄ΠΈΠ»ΠΈ Π»Π΅Ρ‡Π΅Π½ΠΈΠ΅ Π² нашСм онкологичСском Ρ†Π΅Π½Ρ‚Ρ€Π΅ с 9 апрСля 2020 ΠΏΠΎ 27 мая 2020 Π³ΠΎΠ΄Π° ΠΈ рСгулярно Ρ‚Π΅ΡΡ‚ΠΈΡ€ΠΎΠ²Π°Π»ΠΈΡΡŒ Π½Π° SARS-CoV-2 с ΠΏΠΎΠΌΠΎΡ‰ΡŒΡŽ Π°Π½Π°Π»ΠΈΠ·Π° ΠΏΠΎΠ»ΠΈΠΌΠ΅Ρ€Π°Π·Π½ΠΎΠΉ Ρ†Π΅ΠΏΠ½ΠΎΠΉ Ρ€Π΅Π°ΠΊΡ†ΠΈΠΈ (ПЦР) ΠΈ/ΠΈΠ»ΠΈ COVID-19 Π½Π° ΠΊΠΎΠΌΠΏΡŒΡŽΡ‚Π΅Ρ€Π½ΠΎΠΉ Ρ‚ΠΎΠΌΠΎΠ³Ρ€Π°Ρ„ΠΈΠΈ (КВ) Π³Ρ€ΡƒΠ΄Π½ΠΎΠΉ ΠΊΠ»Π΅Ρ‚ΠΊΠΈ.Π Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚Ρ‹ ΠΈ обсуТдСниС. Π’ Π°Π½Π°Π»ΠΈΠ· Π±Ρ‹Π»ΠΈ Π²ΠΊΠ»ΡŽΡ‡Π΅Π½Ρ‹ 2628 ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ², Ρƒ 119 (4,5 %) ΠΈΠ· ΠΊΠΎΡ‚ΠΎΡ€Ρ‹Ρ… Π±Ρ‹Π» ΠΎΠ±Π½Π°Ρ€ΡƒΠΆΠ΅Π½ COVID-19; 45/119 Π±Ρ‹Π»ΠΈ ПЦР-ΠΏΠΎΠ»ΠΎΠΆΠΈΡ‚Π΅Π»ΡŒΠ½Ρ‹ΠΌΠΈ, 95/119 ΠΈΠΌΠ΅Π»ΠΈ Π²ΠΈΡ€ΡƒΡΠ½ΡƒΡŽ пнСвмонию Π½Π° ΠΊΠΎΠΌΠΏΡŒΡŽΡ‚Π΅Ρ€Π½ΠΎΠΉ Ρ‚ΠΎΠΌΠΎΠ³Ρ€Π°Ρ„ΠΈΠΈ, ΠΈ ΠΎΠ±Π° тСста Π±Ρ‹Π»ΠΈ ΠΏΠΎΠ»ΠΎΠΆΠΈΡ‚Π΅Π»ΡŒΠ½Ρ‹ΠΌΠΈ Ρƒ 21/119. Π’ ΠΎΠ±Ρ‰Π΅ΠΉ слоТности 47,9 % случаСв Π±Ρ‹Π»ΠΈ бСссимптомными, Π° Π² 11,8 % случаСв Π±Ρ‹Π»Π° лСгкая Ρ„ΠΎΡ€ΠΌΠ° COVID-19 с ΠΎΠ΄Π½ΠΈΠΌ симптомом. COVID-19 закончился ΡΠΌΠ΅Ρ€Ρ‚Π΅Π»ΡŒΠ½Ρ‹ΠΌ исходом Π² 2 (2,5 %) ΠΈΠ· 80 случаСв с извСстным исходом. На основании ΠΎΠ΄Π½ΠΎΠ³ΠΎ Ρ‚ΠΎΠ»ΡŒΠΊΠΎ тСста ПЦР, ΠΊΠΎΡ‚ΠΎΡ€Ρ‹ΠΉ использовался для скрининга ΠΊΠ°ΠΊ ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ², Ρ‚Π°ΠΊ ΠΈ пСрсонала, ΡƒΡ€ΠΎΠ²Π΅Π½ΡŒ обнаруТСния вирусов срСди протСстированных Π»ΠΈΡ† составил 3,0 ΠΈ 2,4 % соотвСтствСнно (p = 0,33).Π—Π°ΠΊΠ»ΡŽΡ‡Π΅Π½ΠΈΠ΅. Π‘ΠΊΡ€ΠΈΠ½ΠΈΠ½Π³ онкологичСских Π±ΠΎΠ»ΡŒΠ½Ρ‹Ρ… Π½Π° COVID-19 Π² нашСй ΠΊΠ»ΠΈΠ½ΠΈΠΊΠ΅ ΠΏΠΎΠΊΠ°Π·Ρ‹Π²Π°Π΅Ρ‚, Ρ‡Ρ‚ΠΎ риск зараТСния сущСствСнно Π½Π΅ отличаСтся ΠΎΡ‚ Ρ‚Π°ΠΊΠΎΠ²ΠΎΠ³ΠΎ Ρƒ пСрсонала ΠΊΠ»ΠΈΠ½ΠΈΠΊΠΈ. Одна Ρ‚ΠΎΠ»ΡŒΠΊΠΎ ПЦР ΠΌΠΎΠΆΠ΅Ρ‚ ΠΏΡ€ΠΎΠΏΡƒΡΡ‚ΠΈΡ‚ΡŒ ΠΌΠ½ΠΎΠ³ΠΈΠ΅ случаи COVID-19 Ρƒ онкологичСских Π±ΠΎΠ»ΡŒΠ½Ρ‹Ρ…, ΠΈ Π΅Π³ΠΎ слСдуСт ΡΠΎΡ‡Π΅Ρ‚Π°Ρ‚ΡŒ с КВ. Π˜Π½Ρ„Π΅ΠΊΡ†ΠΈΡ ΠΏΡ€ΠΎΡ‚Π΅ΠΊΠ°Π΅Ρ‚ бСссимптомно ΠΈΠ»ΠΈ Π² Π±ΠΎΠ»ΡŒΡˆΠΈΠ½ΡΡ‚Π²Π΅ случаСв ΠΈΠΌΠ΅Π΅Ρ‚ ΠΌΠΈΠ½ΠΈΠΌΠ°Π»ΡŒΠ½Ρ‹Π΅ клиничСскиС проявлСния
    corecore